The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity
John M. Maris(Children's Hospital of Philadelphia), Michal Zimmermann(Zimmerman Associates (United States))
Cited by 1
Related Papers
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
|New England Journal of Medicine|2005|571
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512